Peter Ruane, MD

Ruane Clinical Research, Los Angeles, CA, USA

Disclosure(s): Gilead Sciences, Inc.: Advisor/Consultant; Merck: Advisor/Consultant; ViiV: Advisor/Consultant

Poster(s):

• (P-365) Pooled safety and tolerability of twice-yearly lenacapavir with teropavimab and zinlirvimab for HIV-1 treatment
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET